m****g
发帖数: 530 | 1 10 February 2010 - The National Institute for Health and Clinical Excellence
(NICE) announced that in draft
guidance published yesterday, it has been unable to recommend everolimus (
afinitor, Novartis (VTX: NOVN))
for the second line treatment of advanced renal cell carcinoma, and that the
guidance is now available for
public consultation.
Consultees, healthcare professionals and members of the public are able to
comment on the
recommendations which are available from 9 February until 2 March 2 | m****g
发帖数: 530 | 2 that is really a bad news for Novartis, let's check its stock. also,this
may also give a chanlenge to those companying who are rushing to develop
mTor targeted anti-cancer therapies, clinically it may not show any real
efficacy. | a****o
发帖数: 1786 | |
|
